AbbVie Inc (ABBV)vsOncology Institute Inc (TOI)
ABBV
AbbVie Inc
$227.23
+0.40%
HEALTHCARE · Cap: $391.50B
TOI
Oncology Institute Inc
$4.87
+2.74%
HEALTHCARE · Cap: $523.91M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 11410% more annual revenue ($62.82B vs $545.76M). ABBV leads profitability with a 5.8% profit margin vs -8.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
TOI
Hold45
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.4%
Fair Value
$146.00
Current Price
$227.23
$81.23 premium
Margin of Safety
-8.7%
Fair Value
$2.41
Current Price
$4.87
$2.46 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Growing faster than its price suggests
Generating 3.6B in free cash flow
Revenue surging 41.2% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -652.0% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : TOI
The strongest argument for TOI centers on Revenue Growth, Debt/Equity. Revenue growth of 41.2% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 108.6x leaves little room for execution misses.
Bear Case : TOI
The primary concerns for TOI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABBV profiles as a value stock while TOI is a hypergrowth play — different risk/reward profiles.
TOI carries more volatility with a beta of 0.41 — expect wider price swings.
TOI is growing revenue faster at 41.2% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 45/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Oncology Institute Inc
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Oncology Institute Inc (ticker: TOI) is a premier healthcare organization dedicated to transforming cancer care through its extensive network of specialized clinics and innovative treatment methodologies. The company leverages advanced technologies and personalized care strategies to enhance patient outcomes, while also prioritizing clinical trials and collaborations with leading research institutions. As the demand for advanced cancer therapies grows, TOI is strategically positioned to capitalize on this market trend, underpinned by a robust pipeline and a deep reservoir of oncology expertise, making it an attractive investment opportunity in the evolving healthcare sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?